Find a Collaborator
Prof Dario CAMPANA
Haematological
Research focus is on the development of innovative technologies to treat cancer with immune cells, and their translation into first-in human clinical trials.
Dr Jit Kong CHEONG
Haematological
Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.
Prof CHNG Wee Joo
Haematological
Research focus is on blood cancers to understand how the disease develops and find better ways to treat them.
Dr Anand Devaprasath JEYASEKHARAN
Haematological
Clinical research focuses on combinatorial drug therapy trials in lymphoma, and methods for evaluating cancer phenotypes for personalized treatment choice. Biological research focuses on understanding the signalling pathways involved in activation of immune responses after chemotherapy.
A/Prof KOH Liang Piu
Haematological
Research focuses mainly on clinical Haematopoietic Stem Cell Transplantation in particular Nonmyeloablative Stem Cell Transplant, haploidentical donor transplant, Umbilical Cord Blood Transplantation in Haematological Malignancies. He also the leading primary investigators on clinical trials on Infectious Complications in Haematological / Haematopoietic Stem Cell Transplantation Recipients, studies on Graft vs. Host Disease prevention and treatment.
A/Prof NG Siok Bian
Haematological
Research focus is to identify and validate novel markers of prognostic and therapeutic importance in EBV-associated T- and NK-cell lymphomas and lymphoproliferative diseases, a group of aggressive tumours which are prevalent in Asia.
Dr OOI Gaik Ming, Melissa
Haematological
She is currently the leukaemia group lead in National University Cancer Institute of Singapore and is also heavily involved in myeloma, leukaemia and myelodysplasia clinical care and research. She is also interested in health service research and geriatric research.
A/Prof YEOH Eng Juh, Allen
Haematological
Research focus is on improving Acute Lymphoblastic Leukaemia treatment in children and adults by better prediction of each patient’s risk of relapse using highly sensitive biomarkers like RNA-Seq and MRD measurements. A/Prof Yeoh works on immune cell therapy especially CAR-T cell therapy for leukaemia with Prof Dario Campana in NUSMed.
Dr ZHOU Jianbiao
Haematological
Research focus is on the drug resistance mechanisms and aggressive phenotypes in hematologic malignancies, as well as the development predictive markers, novel therapeutic targets.
Dr CHEE Cheng Ean
Colorectal
Research interest is in precision oncology in colorectal, pancreas and liver cancers. I develop and conduct clinical trials with novel therapeutics and work with collaborators within and outside Singapore on translational and biomarker research in these areas. In addition, I am interested in healthcare delivery and personalizing care for our cancer survivors.
Dr Jit Kong CHEONG
Gastric
Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.
Prof Yoshiaki ITO
Gastric, Colorectal
Research focuses on the regulation of stem cells and cancer phenotype from two angles: IQGAP3 is a cytoskeletal protein tightly associated with proliferation and stem cell properties of cancer cells. RUNX3 is a transcription factor functions as a gatekeeper of gastric cancer, often silenced by promoter methylation.
Prof SO Bok Yan, Jimmy
Gastric
Research focus is to improve outcomes of patients with gastric or esophageal cancer through early detection, better understanding of their origins and novel treatment.
Dr Sriram SRIDHARAN
Gastric / Colorectal
Research focus is to study how DNA replication is a source of genome instability. I aim to understand why and how the (epi)genome acts as an impediment to faithful DNA replication.
Dr Raghav SUNDAR
Gastric, Colorectal
Research focuses on identifying predictive biomarkers and potential therapeutic targets of systemic therapy in gastric cancer by incorporating contemporary technology such as spatial transcriptomics and machine-learning.
A / Prof YAP Suen Mei, Celestial
Gastric
The expertise and commitment of my research extend expansively across human diseases and human biology including cancer. In addition, we have special interests in the roles of the cytoskeleton in cancer. My research group has developed both in vitro techniques incorporating molecular and bioinformatics technology, as well as in vivo approaches to investigating human diseases such as cancers.
Dr Jit Kong CHEONG
Gastric
Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.
Dr Jit Kong CHEONG
Breast
Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.
A / Prof DENG Lih Wen
Gynaecological
Research focus is on understanding the cellular and molecular mechanism in cancer development and therapy resistance for the development of diagnostic markers and selective therapeutics against cancer resistance and metastasis.
Dr Kong Li Ren
Breast
Research focus is in targeted intervention based on germline mutations.
Dr Alan Prem KUMAR
Breast
Research focus is on uncovering new cues that drive the spread of cancer and develop target-based precision therapies to prevent metastasis in several types of female reproductive cancers.
Prof LEE Soo Chin
Breast
Research focuses on novel therapeutics and predictive biomarkers in breast cancer. Her team has identified a biomarker detectable in blood that predicts breast cancer recurrence, and that can be used to select patients for a novel targeted therapy.
A / Prof LIM Gkeok Stzuan, Diana
Gynaecological
Dr Diana Lim is a senior consultant pathologist and director of the Diagnostic Molecular Oncology Centre (DMOC) in National University Hospital. Her subspecialty and research interest lies in gynaecologic and molecular pathology.
Dr Tai Yee Kit Alex
Breast
Research focus is on exploring the therapeutic benefits of pulsed electromagnetic fields (PEMF) as an exercise-mimetic to enhance the vulnerability of tumor cells to chemotherapy.
A / Prof TAN Shao Peng, David
Gynaecological
Research is focused on the development of biomarkers and novel therapeutic agents in gynaecological cancers; in understanding the mechanisms of treatment response and resistance in these cancers, with the aim of developing biomarkers to help stratify patients into optimal treatment strategies.
Prof Ashok VENKITARAMAN
Breast
Research focus is on deciphering the mechanisms underlying cancer susceptibility to intercept cancer evolution.
A / Prof YAP Suen Mei, Celestial
Breast
The expertise and commitment of my research extend expansively across human diseases and human biology including cancer. In addition, we have special interests in the roles of the cytoskeleton in cancer. My research group has developed both in vitro techniques incorporating molecular and bioinformatics technology, as well as in vivo approaches to investigating human diseases such as cancers.
A / Prof YIP Wai Cheong, George
Breast
Research interest is in understanding the biological roles of molecules called glycosaminoglycans and proteoglycans and to determine if these biomolecules can be used to predict patient outcomes and the development of new treatment.
A / Prof YIP Wai Cheong, George
Breast
Research interest is in understanding the biological roles of molecules called glycosaminoglycans and proteoglycans and to determine if these biomolecules can be used to predict patient outcomes and the development of new treatment.
Dr Jit Kong CHEONG
Liver / Pancreatic
Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.
A / Prof CHEN Leilei, Polly
Liver
Research focus is on identifying how the harmful changes that occur in RNA molecules trigger a cell to develop into cancer which can eventually lead to the unsatisfactory treatment outcomes for patients with cancers. The long-term goal of Dr Chen’s team is to develop novel cancer therapies targeting these cancer-associated RNA changes.
A / Prof CHOW Kai-Hua, Edward
Liver
Research focus is on how to quickly and accurately identify effective cancer therapeutic options for individual cancer patients as well as specific sub-groups of cancer patients in both blood cancers and solid tumours.
Prof Ashok VENKITARAMAN
Pancreatic
Research focus is on deciphering the mechanisms underlying cancer susceptibility to intercept cancer evolution.
New user name
Liver
Research focus is on identifying how the harmful changes that occur in RNA molecules trigger a cell to develop into cancer which can eventually lead to the unsatisfactory treatment outcomes for patients with cancers. The long-term goal of Dr Chen’s team is to develop novel cancer therapies targeting these cancer-associated RNA changes.
A / Prof Gautam SETHI
Lung
Research focus is to elucidate the mechanism(s) of activation of oncogenic transcription factors and identification of novel inhibitors of these proteins for cancer prevention as well as therapy.
Prof Daniel TENEN
Lung
Research focus is on gene regulation in normal cells and cancer, mainly in leukaemia, lung cancer, and liver cancer. Current interests are transcription factors, epigenetics, and weird long noncoding RNAs in these processes, as well as targeting the oncofoetal protein SALL4.
Prof Yang ZHANG
Lung /Thoracic / Head and Neck / Thyroid
Built on cutting-edge artificial intelligence (AI) and deep-learning techniques, we are developing new methods for protein and RNA structure prediction and protein designs. We are particularly interested in the application of the AI-based computational methods for effective cancer therapeutics, with focuses on anti-cancer peptide-drug conjugates (PDCs) and T-cell receptor (TCR)-based adoptive therapy..
Dr Rajeev PARAMESWARAN
Thyroid
Focus of research is to investigate how specific genomic alterations seen in various thyroid cancer phenotypes contribute to aberrant glycan formation that may be associated with thyroid cancer progression and metastasis. Also interested in developing glycan markers to help differentiate between the low-risk and high-risk thyroid cancers preoperatively.